恶性黑素瘤,嵌合型抗原受体T细胞,肿瘤免疫微环境," /> 恶性黑素瘤,嵌合型抗原受体T细胞,肿瘤免疫微环境,"/> malignant melanoma, chimeric antigen receptor T cells, tumor immune microenvironment,"/> 嵌合型抗原受体T细胞在恶性黑色素瘤中应用进展

中国麻风皮肤病杂志 ›› 2024, Vol. 40 ›› Issue (1): 59-65.doi: 10.12144/zgmfskin202401059

• 综述 • 上一篇    下一篇

嵌合型抗原受体T细胞在恶性黑色素瘤中应用进展

张立坤1,岳武恒2,邹征云3   

  1. 1南京中医药大学太仓附属医院皮肤科，江苏太仓， 215400；2南京中医药大学太仓附属医院肿瘤科，江苏太仓， 215400；3南京大学医学院附属鼓楼医院肿瘤中心，江苏南京，210008
  • 出版日期:2024-01-15 发布日期:2023-12-25

Update of chimeric antigen receptor T cell in malignant melanoma

ZHANG Likun1, YUE Wuheng2, ZOU Zhengyun3   

  1. 1 Department of Dermatology，Taicang TCM Hospital Affiliated to Nanjing University of Chinese Medicine，Taicang 215400, China; 2 Department of Oncology, Taicang TCM Hospital Affiliated to Nanjing University of Chinese Medicine，Taicang 215400, China; 3 The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China
  • Online:2024-01-15 Published:2023-12-25

PDF (PC)

188

摘要： 恶性黑素瘤细胞膜表达有多种生物标志物，可作为治疗靶点开发针对性的嵌合型抗原受体T细胞（CAR-T），CAR-T目前对恶性黑素瘤中GD2、HER2、CD70、Gp100、NYESO-1等靶点已表现出良好的疗效。本文旨在梳理恶性黑素瘤CAR-T靶点及临床进展，分析工程化T细胞的挑战与应对之策，以期CAR-T应用于恶性黑素瘤临床实践。

关键词: 恶性黑素瘤')">">恶性黑素瘤, 嵌合型抗原受体T细胞, 肿瘤免疫微环境

Abstract: There are a variety of biomarkers expressed on the membrane of malignant melanoma cells, which can be used as therapeutic targets to develop targeted chimeric antigen receptor T cells (CAR-T). CAR-T has shown good effects on GD2, HER2, CD70, Gp100, NYESO-1 and other targets in malignant melanoma. This paper aims to review the targets and clinical progress of CAR-T cells for malignant melanoma, and analyze the challenges and countermeasures of engineered T cells, in order to apply CAR-T cells to the clinical practice of malignant melanoma.

Key words: malignant melanoma')">">malignant melanoma, chimeric antigen receptor T cells, tumor immune microenvironment